Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Brian S. Chang is active.

Publication


Featured researches published by Brian S. Chang.


Molecular and Cellular Biology | 1997

Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL.

Ameeta Kelekar; Brian S. Chang; John E. Harlan; Stephen W. Fesik; Craig B. Thompson

The Bcl-2 related protein Bad is a promoter of apoptosis and has been shown to dimerize with the anti-apoptotic proteins Bcl-2 and Bcl-XL. Overexpression of Bad in murine FL5.12 cells demonstrated that the protein not only could abrogate the protective capacity of coexpressed Bcl-XL but could accelerate the apoptotic response to a death signal when it was expressed in the absence of exogenous Bcl-XL. Using deletion analysis, we have identified the minimal domain in the murine Bad protein that can dimerize with Bcl-xL. A 26-amino-acid peptide within this domain, which showed significant homology to the alpha-helical BH3 domains of related apoptotic proteins like Bak and Bax, was found to be necessary and sufficient to bind Bcl-xL. To determine the role of dimerization in regulating the death-promoting activity of Bad and the death-inhibiting activity of Bcl-xL, mutations within the hydrophobic BH3-binding pocket in Bcl-xL that eliminated the ability of Bcl-xL to form a heterodimer with Bad were tested for the ability to promote cell survival in the presence of Bad. Several of these mutants retained the ability to impart protection against cell death regardless of the level of coexpressed Bad protein. These results suggest that BH3-containing proteins like Bad promote cell death by binding to antiapoptotic members of the Bcl-2 family and thus inhibiting their survival promoting functions.


The EMBO Journal | 1997

Identification of a novel regulatory domain in Bcl‐xL and Bcl‐2

Brian S. Chang; Andy J. Minn; Steven W. Muchmore; Stephen W. Fesik; Craig B. Thompson

Bcl‐xL, a member of the Bcl‐2 family, can inhibit many forms of programed cell death. The three‐dimensional structure of Bcl‐xL identified a 60 amino acid loop lacking defined structure. Although amino acid sequence within this region is not conserved among Bcl‐2 family members, structural modeling suggested that Bcl‐2 also contains a large unstructured region. Compared with the full‐length protein, loop deletion mutants of Bcl‐xL and Bcl‐2 displayed an enhanced ability to inhibit apoptosis. Despite enhanced function, the deletion mutants did not have significant alterations in the ability to bind pro‐apoptotic proteins such as Bax. The loop deletion mutant of Bcl‐2 also displayed a qualitative difference in its ability to inhibit apoptosis. Full‐length Bcl‐2 was unable to prevent anti‐IgM‐induced cell death of the immature B cell line WEHI‐231. In contrast, the Bcl‐2 deletion mutant protected WEHI‐231 cells from death. Substantial differences were observed in the ability of WEHI‐231 cells to phosphorylate the deletion mutant of Bcl‐2 compared with full‐length Bcl‐2. Bcl‐2 phosphorylation was found to be dependent on the presence of an intact loop domain. These results suggest that the loop domain in Bcl‐xL and Bcl‐2 can suppress the anti‐apoptotic function of these genes and may be a target for regulatory post‐translational modifications.


The EMBO Journal | 1999

Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms

Andy J. Minn; Claudia S. Kettlun; Heng Liang; Ameeta Kelekar; Matthew G. Vander Heiden; Brian S. Chang; Steven W. Fesik; Michael Fill; Craig B. Thompson

A hydrophobic cleft formed by the BH1, BH2 and BH3 domains of Bcl‐xL is responsible for interactions between Bcl‐xL and BH3‐containing death agonists. Mutants were constructed which did not bind to Bax but retained anti‐apoptotic activity. Since Bcl‐xL can form an ion channel in synthetic lipid membranes, the possibility that this property has a role in heterodimerization‐independent cell survival was tested by replacing amino acids within the predicted channel‐forming domain with the corresponding amino acids from Bax. The resulting chimera showed a reduced ability to adopt an open conductance state over a wide range of membrane potentials. Although this construct retained the ability to heterodimerize with Bax and to inhibit apoptosis, when a mutation was introduced that rendered the chimera incapable of heterodimerization, the resulting protein failed to prevent both apoptosis in mammalian cells and Bax‐mediated growth defect in yeast. Similar to mammalian cells undergoing apoptosis, yeast cells expressing Bax exhibited changes in mitochondrial properties that were inhibited by Bcl‐xL through heterodimerization‐dependent and ‐independent mechanisms. These data suggest that Bcl‐xL regulates cell survival by at least two distinct mechanisms; one is associated with heterodimerization and the other with the ability to form a sustained ion channel.


Molecular and Cellular Biology | 1999

The BH3 Domain of Bcl-x S Is Required for Inhibition of the Antiapoptotic Function of Bcl-x L

Brian S. Chang; Ameeta Kelekar; Marian H. Harris; John E. Harlan; Stephen W. Fesik; Craig B. Thompson

ABSTRACT bcl-x is a member of the bcl-2 family of genes. The major protein product, Bcl-xL, is a 233-amino-acid protein which has antiapoptotic properties. In contrast, one of the alternatively spliced transcripts of the bcl-xgene codes for the protein Bcl-xS, which lacks 63 amino acids present in Bcl-xL and has proapoptotic activity. Unlike other proapoptotic Bcl-2 family members, such as Bax and Bak, Bcl-xS does not seem to induce cell death in the absence of an additional death signal. However, Bcl-xS does interfere with the ability of Bcl-xL to antagonize Bax-induced death in transiently transfected 293 cells. Mutational analysis of Bcl-xS was conducted to identify the domains necessary to mediate its proapoptotic phenotype. Deletion mutants of Bcl-xS which still contained an intact BH3 domain retained the ability to inhibit survival through antagonism of Bcl-xL. Bcl-xS was able to form heterodimers with Bcl-xL in mammalian cells, and its ability to inhibit survival correlated with the ability to heterodimerize with Bcl-xL. Deletion mutants of Bax and Bcl-2, which lacked BH1 and BH2 domains but contained a BH3 domain, were able to antagonize the survival effect conferred by Bcl-xL. The results suggest that BH3 domains from both pro- and antiapoptotic Bcl-2 family members, while lacking an intrinsic ability to promote programmed cell death, can be potent inhibitors of Bcl-xL survival function.


Urology | 2001

Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma

Brian S. Chang; Hyung L. Kim; X. Yang; Gary D. Steinberg

OBJECTIVES To assess the degree of correlation between the pathologic characteristics of the specimens obtained from biopsy and radical cystoprostatectomy. The stage and grade of bladder urothelial (transitional cell) carcinoma are important predictors of prognosis. METHODS We retrospectively identified 169 cases of urothelial carcinoma from 222 radical cystectomies performed at University of Chicago Hospitals from 1992 to 1999. RESULTS For all the cases in this study, the histologic grade, using the 1998 World Health Organization and International Society of Urological Pathologists (WHO/ISUP) classification, was identical when the biopsy specimen and radical cystectomy specimen were compared. However, when the same cases were assessed using the traditional three-grade system, the histologic grade increased or decreased by one grade in 19 (11%) and 8 (5%) of 169 cases, respectively. Patients with invasion of the lamina propria on biopsy had tumor extending outside the bladder in 15 (27%) of 55 cases. Patients with invasion of the muscularis propria on biopsy had tumor extending outside the bladder in 47 (49%) of 96 cases, including nodal metastasis in 22 (23%) of 96 cases. Overall, bladder biopsy underestimated the true extent of the disease in 78 (46%) of 169 cases. CONCLUSIONS Using either the WHO/ISUP (1998) classification or the traditional three-grade system, the histologic grade of the biopsy specimen is a fairly good predictor of the final histologic grade. The preoperative biopsy tends to understage bladder cancer. Patients with muscularis propria invasion demonstrated by biopsy have a significantly higher risk of non-organ-confined disease than those with lamina propria invasion.


International Journal of Radiation Oncology Biology Physics | 1998

'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosis.

Stuart H. Burri; Caryn Naekyung Kim; Guofu Fang; Brian S. Chang; Charles Perkins; Wayne Harris; Lawrence W. Davis; Craig B. Thompson; Kapil N. Bhalla

PURPOSE/OBJECTIVE To investigate the effect of the enforced expression of p29Bcl-xL or its loop deletional mutant, p18Bcl-xLdelta, on irradiation-induced apoptosis and cell-cycle distribution of HL-60 cells. MATERIALS & METHODS We compared the irradiation-induced molecular cascade of apoptosis in control human AML HL-60/neo versus Bcl-xL overexpressing (approximately 8-fold) (HL-60/Bcl-xL) and HL-60/Bcl-XLdelta cells that express the loop domain deletional mutant construct (delta26-83 AA) of Bcl-xL. The three cell lines were irradiated with 6MV photons to varying doses up to 20 Gy. Following this, cytosolic cyt c levels, caspase-3 activity, and the Bcl-2 family of proteins were evaluated utilizing Western blot analysis (whole cell lysate or cytosolic S-100 fraction). Apoptosis was assessed by internucleosomal DNA fragmentation, Annexin-V staining and FACS analysis, as well as by morphologic criteria. The cell-cycle effects of radiation were analyzed by flow cytometry. RESULTS Eight hours following irradiation (12 Gy) of HL-60/neo cells, a marked increase (approximately 8-fold) in the cytosolic accumulation of cyt c in the S-100 fraction was observed. This was associated with the cleavage of caspase-3, as well as the generation of its poly (ADP-ribose) polymerase (PARP) and DFF (DNA fragmentation factor)-45 cleavage activity. Twenty-four to forty-eight hours after irradiation, internucleosomal DNA fragmentation and positive Annexin-V staining (32.3+/-3.3%) was detected in HL-60/neo cells. In contrast, in both HL-60/Bcl-xL and HL-60/Bcl-xLdelta cells, a significantly lower percentage of apoptotic cells (p<0.05) were detected and internucleosomal DNA fragmentation was not induced. Following irradiation, Western analysis neither demonstrated any significant alteration in Bcl-2, p29Bcl-xL, p18Bcl-xLdelta, or Bax; nor induced CD95 (Fas receptor) or Fas ligand expression in any cell type. However, in all cell types, irradiation produced approximately a 2-fold increase in the percentage of cells in the G2/M phase of the cell cycle. CONCLUSION These results demonstrate that an intact loop domain is not necessary for the full antiapoptotic function of Bcl-xL against irradiation-induced cytosolic accumulation of cyt c, caspase activation, and apoptosis of HL-60 cells. Additionally, the cell-cycle effects of ionizing radiation in HL-60 cells are not affected by enforced expression of Bcl-xL or Bcl-xLdelta.


Nature | 1996

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death.

Steven W. Muchmore; Michael Sattler; Heng Liang; Robert P. Meadows; John E. Harlan; Ho Sup Yoon; David G. Nettesheim; Brian S. Chang; Craig B. Thompson; Sui-Lam Wong; Shi-Chung Ng; Stephen W. Fesik


Science | 1997

Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis

Michael Sattler; Heng Liang; David G. Nettesheim; Robert P. Meadows; John E. Harlan; Matthias Eberstadt; Ho Sup Yoon; Suzanne B. Shuker; Brian S. Chang; Andy J. Minn; Craig B. Thompson; Stephen W. Fesik


Cancer Research | 1998

'Loop' domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis

Guofu Fang; Brian S. Chang; Caryn Naekyung Kim; Charles Perkins; Craig B. Thompson; Kapil N. Bhalla


International Journal of Radiation Oncology Biology Physics | 2017

A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)

M. Dror Michaelson; Chen Hu; Huong T. Pham; Douglas M. Dahl; Chin Lee-Wu; Gregory P. Swanson; Jacqueline Vuky; R. Jeffrey Lee; Luis Souhami; Brian S. Chang; Asha George; Howard M. Sandler; William U. Shipley

Collaboration


Dive into the Brian S. Chang's collaboration.

Top Co-Authors

Avatar

Craig B. Thompson

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Heng Liang

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar

John E. Harlan

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andy J. Minn

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Steven W. Muchmore

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David G. Nettesheim

University of Wisconsin–Milwaukee

View shared research outputs
Researchain Logo
Decentralizing Knowledge